Keryx Biopharmaceuticals Inc (NASDAQ:KERX)
During the Trading Day
| 8.05 |  +0.11 / +1.39% |
Data as of 4:00pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 8.05 |  0.00 / 0.00% |
Volume: 1.2K |
Latest KERX News | Press Releases
| Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE) 10:42am / TheStreet.com | Rockwell Medical Run-Up Trade Follows Financing 8:08am / TheStreet.com |
Today’s Trading
| Previous close | 7.94 |
| Today’s open | 7.99 |
| Day’s range | 7.87 - 8.20 |
| Volume | 1,392,027 |
| Average volume (3 months) | 2,961,943 |
| Market cap | $648.8M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/21/2013
Growth & Valuation
| Earnings growth (last year) | +15.71% |
| Earnings growth (this year) | +4.02% |
| Earnings growth (next 5 years) | +30.00% |
| Revenue growth (last year) | -100.00% |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 54.42 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| IDIXIdenix Pharmaceutica... | +0.01 | +0.25% |
| NXTMNxstage Medical Inc | +0.12 | +0.90% |
| EXELExelixis Inc | +0.12 | +2.67% |
| SGYPSynergy Pharmaceutic... | -0.23 | -4.43% |
Data as of 4:00pm ET, 05/21/2013
Financials
| Next reporting date | August 12, 2013 |
| EPS forecast (this quarter) | -$0.10 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$25.4M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Ronald Bentsur, MBA |
Chief Financial Officer, Secretary & Treasurer James F. Oliviero, III, CFA |
Corporate headquarters New York, New York |
Forecasts
